Stock comparison

BMYvsLLY

Bristol-Myers Squibb CovsEli Lilly and Co. Real data pulled from the alphactor.ai fundamentals pipeline — valuation, balance-sheet health, momentum, and analyst sentiment side by side.

BMY

Bristol-Myers Squibb Co

$59.02

+8.71%

Pharmaceuticals$117.4BNYSE

LLY

Eli Lilly and Co

$903.02

-12.12%

Pharmaceuticals$884.0BNYSE

60-day price, rebased to 100

BMY +8.73% · LLY -11.80%

Round-by-round

BMY 3·LLY 3

EdgeBMY

Valuation upside

+2.90% vs -70.20% to DCF fair value

EdgeLLY

Balance-sheet strength

Altman Z 2.20 vs 8.14

EdgeBMY

Fundamental quality

Piotroski 9.00 vs 8.00 (of 9)

EdgeLLY

Growth + margins

Rule-of-40 26.40 vs 53.90

EdgeBMY

60-day momentum

+8.73% vs -11.80% price return

EdgeLLY

Market-cap liquidity

$117.4B vs $884.0B

Verdict

Across6categories,the two names are evenly matched —3wins each. Neither score is a buy signal on its own: run the full backtest and credibility tests on alphactor.ai before putting money on it.

Backtest a strategy onBMYorLLY

Point-in-time backtests, 8-layer credibility pipeline, conviction scoring — free to start.